A trial can be perfectly designed, ethically conducted, and scientifically sound, and still fail at the regulatory gate because of how its data was handled. The data infrastructure is not a support function. It is the trial.
What data-driven trials really demand
The phrase ‘data-driven trial’ gets used freely, but its practical meaning is narrow: the ability to act on data signals in real time rather than finding problems after the fact. Modern designs have made this unavoidable. An early-phase oncology study taking intensive PK and biomarker samples, or a trial with electronic patient-reported outcomes and biosensor feeds from home, generates data faster than any end-of-study review can absorb. ICH E6(R3), now in effect across the major regions, makes the same point in regulatory terms: quality has to be designed in and managed by risk as the trial runs, not inspected for once recruitment closes.
Real-time surveillance moves quality control upstream: automated flags on implausible values, cross-form consistency checks, and monitoring of data-entry velocity mean a critical discrepancy surfaces within 24 hours rather than two weeks before lock. Site and vendor performance analytics add another layer. Tracking query rates, protocol deviation frequencies, and data-entry lag shows where a study is struggling early enough to intervene, before weak data compromises the wider dataset.
“The best data management system makes it impossible to enter bad data quietly. Every discrepancy should surface immediately, not at lock.”
This shift from reactive to proactive oversight is not a technology upgrade. It is a change in what quality means: no longer a checkpoint at the end of a study but a continuous property of the trial itself.
What data integrity failures actually look like
Regulatory inspection findings follow recognisable patterns. Audit trails disabled or manipulated. Data entered retrospectively without documentation. Source records that cannot be reconciled with eCRF entries. Analysis datasets with no traceable path back to raw data. These are not rare edge cases, they appear repeatedly across sponsors and contract research organisations of every size.
ALCOA+ principles are widely cited but unevenly applied. ‘Attributable’ means every data point has an identified, accountable source, not a shared login. ‘Contemporaneous’ means recorded at the time of observation, not reconstructed from memory days later. Inspectors are trained to find exactly these gaps, and they do.
Analytical reproducibility is an equally important and often overlooked dimension. Regulators increasingly expect that any result in a submission package can be reproduced from raw data using documented, version-controlled code. Analysis scripts that rely on undocumented manual steps, or that exist only on a single analyst’s workstation, represent an integrity risk that is straightforward to prevent and very difficult to defend once identified.
The challenges no one plans for – but should
Protocol amendments are among the most disruptive events a data team faces, and early-phase studies amend often: a dose-escalation cohort triggers a change to dosing, a safety signal tightens inclusion criteria, an emerging endpoint is added. Each change can ripple through every collection instrument, validation rule, and analysis specification, under time pressure and without compromising the blind. A modular, well-documented data system absorbs that far more easily than a bespoke configuration built around one programmer’s knowledge.
Multi-vendor reconciliation is a related and underestimated challenge, and it is not only a large-trial problem. Even a compact early-phase study pulls in central laboratory feeds, IRT records, PK and biomarker results, and sometimes imaging, all of which have to reconcile into one analysis-ready dataset. Mismatched patient identifiers, timing discrepancies, and unit inconsistencies cannot be sorted out at lock. They call for data governance agreements with every vendor from study start, fixing transfer formats, schedules, and reconciliation procedures before the first patient enrols.
Running across borders adds regulatory heterogeneity on top of operational complexity, and early-phase programmes increasingly span more than one country. Data privacy rules vary by jurisdiction, some markets require local data residency, and consent language can affect how data is pooled across regions. A study that meets these constraints for the first time during data compilation, rather than at protocol design, pays for the oversight in months, not weeks.
“Every data problem that surfaces at lock was a planning gap at study start. The question is not whether problems will arise, but whether the system was built to absorb them.”
How Alpha Clinical is built for this
At Alpha Clinical, data management and biostatistics work within a single quality framework, so integrity controls are not retrofitted at the end of a study. They are built into the collection architecture before the first patient enrols. Validation rules, audit-trail configuration, and discrepancy workflows are specified at eCRF build, not discovered at lock.
Two things sit behind that. Alpha Clinical is pharmacovigilance-led, so data integrity and patient safety run through the work by default rather than being bolted on. And most of our sponsors are early-phase biotechs, often with one asset and a lean team, where a dataset that will not hold is not an option. We concentrate in oncology, rare disease, gastroenterology and the microbiome, and neuroscience, and with the team spread across the UK, US, Canada, Singapore, and the UAE, oversight carries on across time zones rather than pausing overnight.
On the analytical side, all analysis code is version-controlled, peer-reviewed, and executed in validated computational environments. Every table, listing, and figure in a submission package is traceable back through ADaM to SDTM to raw source data. That chain of custody is not an aspiration at Alpha Clinical, it is a documented, auditable deliverable on every programme we support.
For an early-phase company, the infrastructure decisions made before the first patient enrols are the ones that determine whether the submission holds together years later. They are also the cheapest to get right at the start, and the most expensive to fix at lock.
Ready to discuss your trial’s data infrastructure?
Contact Alpha Clinical Development to learn how our integrated approach to data management and biostatistics protects your programme from protocol to submission.
Sophia Nematollahi
